

DAFTAR PUSTAKA

- Ali, N., 2020. Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19. *Journal of medical virology*. United States. 2409–2411. doi: 10.1002/jmv.26097.
- Armstrong, E. J., Morrow, D. A. and Sabatine, M. S., 2006. Inflammatory biomarkers in acute coronary syndromes: part II: acute-phase reactants and biomarkers of endothelial cell activation. *Circulation*. 113(7), e152-5. doi: 10.1161/CIRCULATIONAHA.105.595538.
- Azevedo, R. B. *et al.*, 2021. Covid-19 and the cardiovascular system: a comprehensive review. *Journal of Human Hypertension*. 35(1), 4–11. doi: 10.1038/s41371-020-0387-4.
- Bihan, H. *et al.*, 2021. Epicardial adipose tissue and severe Coronavirus Disease 19. *Cardiovascular diabetology*. 20(1), 147. doi: 10.1186/s12933-021-01329-z.
- Chong, P. Y. *et al.*, 2004. Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis. *Arch Pathol Lab Med*. 128(2), 195–204. doi: 10.1043/1543-2165(2004)128<195:AODDTS>2.0.CO;2.
- Christensen, B. *et al.*, 2020. Hematology Laboratory Abnormalities in Patients with Coronavirus Disease 2019 (COVID-19). *Seminars in Thrombosis and Hemostasis*. 46(7), 845–849. doi: 10.1055/s-0040-1715458.
- Conte, C. *et al.*, 2021. Epicardial adipose tissue characteristics, obesity and clinical outcomes in COVID-19: A post-hoc analysis of a prospective cohort study. *Nutrition, metabolism, and cardiovascular diseases: NMCD*. 31(7), 2156–2164. doi: 10.1016/j.numecd.2021.04.020.
- Cooper, L. T., 2010. Myocarditis. *The New England Journal of Medicine*. 11(3), 369–373.
- Das, S. K., 2020. The Pathophysiology, Diagnosis and Treatment of Corona Virus Disease 2019 (COVID-19). *Indian Journal of Clinical Biochemistry*. 35(4), 385–396. doi: 10.1007/s12291-020-00919-0.

- Dhakal, B. P. *et al.*, 2020. SARS-CoV-2 Infection and Cardiovascular Disease: COVID-19 Heart. *Heart, Lung and Circulation*. 29, 973–987. Available at:
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7135863/pdf/main.pdf>.
- Duman, Hakan *et al.*, 2019. Relationship Between C-Reactive Protein to Albumin Ratio and Thrombus Burden in Patients With Acute Coronary Syndrome. *Clinical and Applied Thrombosis/Hemostasis*. 25, 1–6. doi: 10.1177/1076029618824418.
- Erdöl, M. A. *et al.*, 2022. The predictive value of epicardial fat volume for clinical severity of COVID-19. *Revista portuguesa de cardiologia: orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology: an official journal of the Portuguese Society of Cardiology*. 41(9), 729–737. doi: 10.1016/j.repc.2021.05.016.
- European Society of cardiology. 2020. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. *European heart journal*. 1–115.
- Ghahramani, S. *et al.*, 2020. Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: A systematic review and meta-analysis. *European Journal of Medical Research*. 25(1), 1–10. doi: 10.1186/s40001-020-00432-3.
- Grodecki, K. *et al.*, 2020. Epicardial adipose tissue is associated with extent of pneumonia and adverse outcomes in patients with COVID-19. *Metabolism Clinical and Experimental*. 115(154436), 1–8. doi: <https://doi.org/10.1016/j.metabol.2020.154436>.
- Guan, W. *et al.*, 2020. Clinical Characteristics of Coronavirus Disease 2019 in China. *New England Journal of Medicine*. 382(18), 1708–1720. doi: 10.1056/nejmoa2002032.
- Guo, J. *et al.*, 2020. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *Journal of the American Heart Association*. 9(7),

e016219. doi: 10.1161/JAHA.120.016219.

- Guzik, T. J. *et al.*, 2020. COVID-19 and the cardiovascular system: Implications for risk assessment, diagnosis, and treatment options', *Cardiovascular Research*. 116(10), 1666–1687. doi: 10.1093/cvr/cvaa106.
- Hemalatha Rajkumar, P. B., 2013. The Impact of Obesity on Immune Response to Infection and Vaccine: An Insight into Plausible Mechanisms', *Endocrinology & Metabolic Syndrome*. 02(02). doi: 10.4172/2161-1017.1000113.
- Hendren, N. S. *et al.*, 2020. Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome. *Circulation*. 141(23), 1903–1914. doi: 10.1161/CIRCULATIONAHA.120.047349.
- Huang, C. *et al.*, 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*, 395(10223), 497–506. doi: [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5).
- Iacobellis, G. *et al.*, 2020. Epicardial Fat Inflammation in Severe COVID-19. *Obesity*. 28(12), 2260–2262. doi: 10.1002/oby.23019.
- Iacobellis, G. and Malavazos, A. E., 2020. COVID-19 rise in Younger adults with Obesity: Visceral Adiposity can predict the Risk. *Obesity (Silver Spring)*. 10, 0–1. doi: 10.1002/oby.22951.
- Kementerian Kesehatan Republik Indonesia. 2014. *Lingkungan Sehat, Jantung Sehat*. Available at: www.depkes.go.id (Accessed: 8 May 2021).
- Kim, I., 2020. Epicardial adipose tissue : fuel for COVID-19- induced cardiac injury ?. *European Heart Journal*. 00, 1–2. doi: 10.1002/oby.22831.
- Kimura, K. *et al.*, 2019. JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome. *Circulation Journal*. 83(5), 1085–1196. doi: 10.1253/circj.CJ-19-0133.
- Kosmeri, C. *et al.*, 2020. Hematological manifestations of SARS-CoV-2 in children. *Pediatric Blood and Cancer*. 67(12). doi: 10.1002/pbc.28745.

- Liu, F. *et al.*, 2020. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. *Journal of Clinical Virology*. 127(104370), 1–5. doi: 10.1016/j.jcv.2020.104370.
- Liu, K., Wang, X. and Song, G., 2022. Association of epicardial adipose tissue with the severity and adverse clinical outcomes of COVID-19: A meta-analysis. *International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases*. 120, 33–40. doi: 10.1016/j.ijid.2022.04.013.
- Luo, X. *et al.*, 2020. Prognostic value of C-reactive protein in patients with COVID-19. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*. 71(16), 2174–2179. doi: 10.1093/cid/ciaa641.
- Madjid, M. *et al.*, 2020. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. *JAMA Cardiology*. 831–840. doi: 10.1001/jamacardio.2020.1286.
- Makki, N., Brennan, T. M. and Girotra, S., 2015. Acute coronary syndrome. *Journal of Intensive Care Medicine*. 30(4), 186–200. doi: 10.1177/0885066613503294.
- Malavazos, A. E., Goldberger, J. J. and Iacobellis, G., 2020. Does epicardial fat contribute to COVID-19 myocardial inflammation?. *European Heart Journal*. 41(24), 2333. doi: 10.1093/eurheartj/ehaa471.
- Mehta, R. *et al.*, 2022. Epicardial adipose tissue thickness is associated with increased COVID-19 severity and mortality. *International journal of obesity (2005)*. 46(4), 866–873. doi: 10.1038/s41366-021-01050-7.
- Melillo, F. *et al.*, 2022. Myocardial injury in patients with SARS-CoV-2 pneumonia: Pivotal role of inflammation in COVID-19. *European journal of clinical investigation*. 52(1), e13703. doi: 10.1111/eci.13703.
- Mihardja, L. *et al.*, 2013. *Penyakit Tidak Menular*. Jakarta: Kementerian Kesehatan Republik Indonesia.

- Montalescot, G., 2007. On behalf of the OPERA investigators. STEMI and NSTEMI are two distinct pathophysiological entities: reply. *Eur Heart J.* 21, 2685–6.
- Mousavizadeh, L. and Ghasemi, S., 2020. Genotype and phenotype of COVID-19: Their roles in pathogenesis. *Journal of Microbiology, Immunology and Infection.* 0–4. doi: 10.1016/j.jmii.2020.03.022.
- Ornelas-Ricardo, D. and Jaloma-Cruz, A. R., 2020. Coronavirus Disease 2019: Hematological Anomalies and Antithrombotic Therapy. *The Tohoku journal of experimental medicine.* 251(4), 327–336. doi: 10.1620/tjem.251.327.
- Ponti, G. *et al.*, 2020. Biomarkers associated with COVID-19 disease progression. *Critical Reviews in Clinical Laboratory Sciences.* 0(0), 1–11. doi: 10.1080/10408363.2020.1770685.
- Rilantono and Rahajoe. 2014. *Penyakit Kardiovaskular pada Perempuan: Tantangan Abad Ke-21.* Jakarta: Badan Penerbit Fakultas Kedokteran Universitas Indonesia.
- Rossi, A. P. *et al.*, 2022. Epicardial adipose tissue volume and CT-attenuation as prognostic factors for pulmonary embolism and mortality in critically ill patients affected by COVID-19. *European journal of clinical nutrition.* 77(1), 105–111. doi: 10.1038/s41430-022-01197-0.
- Ryan, P. M. D. and Caplice, N. M., 2020. Is Adipose Tissue a Reservoir for Viral Spread, Immune Activation, and Cytokine Amplification in Coronavirus Disease 2019?. *Obesity.* 28(7), 1191–1194. doi: 10.1002/oby.22843.
- Rychter, A. M. *et al.*, 2020. Should patients with obesity be more afraid of COVID-19?. *Obesity Reviews.* 21(9), 1–8. doi: 10.1111/obr.13083.
- Sahua, B. R. *et al.*, 2020. C-reactive protein: A promising biomarker for poor prognosis in COVID-19 infection. *Clinica chimica acta; international journal of clinical chemistry.* 509, 91–94. doi: 10.1016/j.cca.2020.06.013.

- Schiavone, M. *et al.*, 2020. Acute Coronary Syndromes and Covid-19: Exploring the Uncertainties. *Journal of Clinical Medicine*. 9(6), 1683. doi: 10.3390/jcm9061683.
- Sevilla, T. *et al.*, 2021. Epicardial adipose tissue attenuation in admitted patients with COVID-19. *Revista espanola de cardiologia (English ed.)*. Spain, 98–100. doi: 10.1016/j.rec.2021.07.006.
- Stringer, D. *et al.*, 2021. The role of C-reactive protein as a prognostic marker in COVID-19. *International journal of epidemiology*. 50(2), 420–429. doi: 10.1093/ije/dyab012.
- Tajbakhsh, A. *et al.*, 2021. *COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up, Expert Review of Anti-Infective Therapy*. Taylor & Francis. doi: 10.1080/14787210.2020.1822737.
- Wang, D. *et al.*, 2020. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA - Journal of the American Medical Association*. 323(11), 1061–1069. doi: 10.1001/jama.2020.1585.
- Wang, W. *et al.*, 2019a. High sensitivity C-reactive protein to prealbumin ratio measurement as a marker of the prognosis in acute coronary syndrome. *Scientific Reports*. 9(1), 11583. doi: 10.1038/s41598-019-48189-y.
- Wang, W. *et al.*, 2019b. Prognostic efficacy of high-sensitivity C-reactive protein to albumin ratio in patients with acute coronary syndrome. *Biomarker in Medicine*. 13(10), 811–820.
- Wei, Z. *et al.*, 2021. Pre-existing Health Conditions and Epicardial Adipose Tissue Volume: Potential Risk Factors for Myocardial Injury in COVID-19 Patients. 7, 1–10. doi: 10.3389/fcvm.2020.585220.
- World Health Organization. 2017. *World Heart Day 2017*. Available at: http://www.who.int/cardiovascular_diseases/world-heart-day-2017 (Accessed: 8 May 2021).

- Yamada, T. *et al.*, 2020. Value of leukocytosis and elevated C-reactive protein in predicting severe coronavirus 2019 (COVID-19): A systematic review and meta-analysis. *Clinica Chimica Acta*. 509, 235–243. doi: 10.1016/j.cca.2020.06.008.
- Ye, W. *et al.*, 2020. Dynamic changes of D-dimer and neutrophil-lymphocyte count ratio as prognostic biomarkers in COVID-19. *Respiratory Research*. 21(1), 1–7. doi: 10.1186/s12931-020-01428-7.
- Zhao, Y. *et al.*, 2021. COVID-19 letter to the editor: Epicardial fat inflammation as possible enhancer in COVID-19?. *Metabolism: clinical and experimental*. 117, 154722. doi: 10.1016/j.metabol.2021.154722.
- Zheng, Y.-Y. *et al.*, 2019. COVID-19 and the cardiovascular system. *Nature Reviews Cardiology*. doi: 10.1038/s41569-020-0360-5.

LAMPIRAN

1. Rekomendasi Persetujuan Etik Penelitian



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari.,MMed,PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431



REKOMENDASI PERSETUJUAN ETIK

Nomor : 530/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 19 September 2022

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH22080417	No Sponsor Protokol	
Peneliti Utama	dr. Aulia Thufael Al Farisi	Sponsor	
Judul Peneliti	Hubungan Profil C-Reactive Protein Terhadap Densitas Lemak Epikardial Pada Pasien Corona Virus Disease-19 Derajat sedang dan Derajat Berat dengan Sindrom Koroner Akut di RS Dr. Wahidin Sudirohusodo Makassar		
No Versi Protokol	1	Tanggal Versi	5 Agustus 2022
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RSUP Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input checked="" type="checkbox"/> Fullboard Tanggal 7 September 2022	Masa Berlaku 19 September 2022 sampai 19 September 2023	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan 	
Sekretaris KEP Universitas Hasanuddin	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan 	

Kewajiban Peneliti Utama:

- Menyerahkan Amendemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan